These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 35803902)
1. Stabilization of SAMHD1 by NONO is crucial for Ara-C resistance in AML. Zhang F; Sun J; Tang X; Liang Y; Jiao Q; Yu B; Dai Z; Yuan X; Li J; Yan J; Zhang Z; Fan S; Wang M; Hu H; Zhang C; Lv XB Cell Death Dis; 2022 Jul; 13(7):590. PubMed ID: 35803902 [TBL] [Abstract][Full Text] [Related]
2. Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies. Herold N; Rudd SG; Ljungblad L; Sanjiv K; Myrberg IH; Paulin CB; Heshmati Y; Hagenkort A; Kutzner J; Page BD; Calderón-Montaño JM; Loseva O; Jemth AS; Bulli L; Axelsson H; Tesi B; Valerie NC; Höglund A; Bladh J; Wiita E; Sundin M; Uhlin M; Rassidakis G; Heyman M; Tamm KP; Warpman-Berglund U; Walfridsson J; Lehmann S; Grandér D; Lundbäck T; Kogner P; Henter JI; Helleday T; Schaller T Nat Med; 2017 Feb; 23(2):256-263. PubMed ID: 28067901 [TBL] [Abstract][Full Text] [Related]
3. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia. Schneider C; Oellerich T; Baldauf HM; Schwarz SM; Thomas D; Flick R; Bohnenberger H; Kaderali L; Stegmann L; Cremer A; Martin M; Lohmeyer J; Michaelis M; Hornung V; Schliemann C; Berdel WE; Hartmann W; Wardelmann E; Comoglio F; Hansmann ML; Yakunin AF; Geisslinger G; Ströbel P; Ferreirós N; Serve H; Keppler OT; Cinatl J Nat Med; 2017 Feb; 23(2):250-255. PubMed ID: 27991919 [TBL] [Abstract][Full Text] [Related]
7. SAMHD1 protects cancer cells from various nucleoside-based antimetabolites. Herold N; Rudd SG; Sanjiv K; Kutzner J; Bladh J; Paulin CBJ; Helleday T; Henter JI; Schaller T Cell Cycle; 2017 Jun; 16(11):1029-1038. PubMed ID: 28436707 [TBL] [Abstract][Full Text] [Related]
8. Novel Vpx virus-like particles to improve cytarabine treatment response against acute myeloid leukemia. Nair R; Salinas-Illarena A; Sponheimer M; Wullkopf I; Schreiber Y; Côrte-Real JV; Del Pozo Ben A; Marterer H; Thomas D; Geisslinger G; Cinatl J; Subklewe M; Baldauf HM Clin Exp Med; 2024 Jul; 24(1):155. PubMed ID: 39003408 [TBL] [Abstract][Full Text] [Related]
9. Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens. Rassidakis GZ; Herold N; Myrberg IH; Tsesmetzis N; Rudd SG; Henter JI; Schaller T; Ng SB; Chng WJ; Yan B; Ng CH; Ravandi F; Andreeff M; Kantarjian HM; Medeiros LJ; Xagoraris I; Khoury JD Blood Cancer J; 2018 Oct; 8(11):98. PubMed ID: 30341277 [TBL] [Abstract][Full Text] [Related]
10. SOX11 is a novel binding partner and endogenous inhibitor of SAMHD1 ara-CTPase activity in mantle cell lymphoma. Abdelrazak Morsy MH; Lilienthal I; Lord M; Merrien M; Wasik AM; Sureda-Gómez M; Amador V; Johansson HJ; Lehtiö J; Garcia-Torre B; Martin-Subero JI; Tsesmetzis N; Tao S; Schinazi RF; Kim B; Sorteberg AL; Wickström M; Sheppard D; Rassidakis GZ; Taylor IA; Christensson B; Campo E; Herold N; Sander B Blood; 2024 May; 143(19):1953-1964. PubMed ID: 38237141 [TBL] [Abstract][Full Text] [Related]
11. Targeting SAMHD1 with hydroxyurea in first-line cytarabine-based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT-AML trial. Jädersten M; Lilienthal I; Tsesmetzis N; Lourda M; Bengtzén S; Bohlin A; Arnroth C; Erkers T; Seashore-Ludlow B; Giraud G; Barkhordar GS; Tao S; Fogelstrand L; Saft L; Östling P; Schinazi RF; Kim B; Schaller T; Juliusson G; Deneberg S; Lehmann S; Rassidakis GZ; Höglund M; Henter JI; Herold N J Intern Med; 2022 Dec; 292(6):925-940. PubMed ID: 35934913 [TBL] [Abstract][Full Text] [Related]
12. With me or against me: Tumor suppressor and drug resistance activities of SAMHD1. Herold N; Rudd SG; Sanjiv K; Kutzner J; Myrberg IH; Paulin CBJ; Olsen TK; Helleday T; Henter JI; Schaller T Exp Hematol; 2017 Aug; 52():32-39. PubMed ID: 28502830 [TBL] [Abstract][Full Text] [Related]
13. SAMHD1 inhibits epithelial cell transformation in vitro and affects leukemia development in xenograft mice. Kodigepalli KM; Li M; Bonifati S; Panfil AR; Green PL; Liu SL; Wu L Cell Cycle; 2018; 17(23):2564-2576. PubMed ID: 30474474 [TBL] [Abstract][Full Text] [Related]
15. Expression and Relationship of SAMHD1 with Other Apoptotic and Autophagic Genes in Acute Myeloid Leukemia Patients. Jiang H; Li C; Liu Z; Shengjing Hospital ; Acta Haematol; 2020; 143(1):51-59. PubMed ID: 31434075 [TBL] [Abstract][Full Text] [Related]
16. SAMHD1 modulates in vitro proliferation of acute myeloid leukemia-derived THP-1 cells through the PI3K-Akt-p27 axis. Kodigepalli KM; Bonifati S; Tirumuru N; Wu L Cell Cycle; 2018; 17(9):1124-1137. PubMed ID: 29911928 [TBL] [Abstract][Full Text] [Related]
17. Association of genetic polymorphisms in genes involved in Ara-C and dNTP metabolism pathway with chemosensitivity and prognosis of adult acute myeloid leukemia (AML). Zhu KW; Chen P; Zhang DY; Yan H; Liu H; Cen LN; Liu YL; Cao S; Zhou G; Zeng H; Chen SP; Zhao XL; Chen XP J Transl Med; 2018 Apr; 16(1):90. PubMed ID: 29631596 [TBL] [Abstract][Full Text] [Related]
18. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells. Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565 [TBL] [Abstract][Full Text] [Related]
19. Long noncoding RNA DANCR confers cytarabine resistance in acute myeloid leukemia by activating autophagy via the miR-874-3P/ATG16L1 axis. Zhang H; Liu L; Chen L; Liu H; Ren S; Tao Y Mol Oncol; 2021 Apr; 15(4):1203-1216. PubMed ID: 33638615 [TBL] [Abstract][Full Text] [Related]
20. Defective expression of deoxycytidine kinase in cytarabine-resistant acute myeloid leukemia cells. Song JH; Kim SH; Kweon SH; Lee TH; Kim HJ; Kim HJ; Kim TS Int J Oncol; 2009 Apr; 34(4):1165-71. PubMed ID: 19287976 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]